SN-38-d3

SN-38-d3 is the deuterium labeled SN-38. SN-38 (NK012) is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 (NK012) inhibits DNA and RNA synthesis with IC50s of 0.077 and 1.3 μM, respectively[1][2][3][4].

Product Specifications

CAS Number

[718612-49-8]

Product Name Alternative

NK012-d3

UNSPSC

12352005

Hazard Statement

H301

Target

ADC Payload; Autophagy; Topoisomerase

Type

Isotope-Labeled Compounds

Related Pathways

Antibody-drug Conjugate/ADC Related; Autophagy; Cell Cycle/DNA Damage

Field of Research

Cancer

Purity

98.79

Solubility

DMSO : 25mg/mL (ultrasonic)

Smiles

[2H]C([2H])([2H])CC1=C2C(C(N3C2)=CC([C@](O)(C(OC4)=O)CC)=C4C3=O)=NC5=CC=C(O)C=C51

Molecular Formula

C22H17D3N2O5

Molecular Weight

395.42

Precautions

H301

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Kawato Y, et al. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 1991;51 (16) :4187-4191.|[3]Wallin A, et al. Anticancer effect of SN-38 on colon cancer cell lines with different metastatic potential. Oncol Rep. 2008 Jun;19 (6) :1493-8.|[4]Jensen NF, et al. Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a newpair of resistance-associated mutations. J Exp Clin Cancer Res. 2016 Mar 31;35:56.